Drug Profile
Research programme: fibrotic diseases therapeuitcs - Boehringer Ingelheim/Harvard Stem Cell Institute
Latest Information Update: 28 Jul 2020
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim; Harvard Stem Cell Institute
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Idiopathic pulmonary fibrosis; Kidney disorders; Non-alcoholic steatohepatitis
Most Recent Events
- 28 Jul 2020 No recent reports of development identified for research development in Idiopathic-pulmonary-fibrosis in USA
- 28 Jul 2020 No recent reports of development identified for research development in Kidney-disorders in USA
- 28 Jul 2020 No recent reports of development identified for research development in Non-alcoholic-steatohepatitis in USA